Renal-Cell Cancer — Targeting an Immune Checkpoint or Multiple Kinases
Menés respectivement sur 658 et 821 patients atteints d'un carcinome à cellules rénales de stade avancé, ces deux essais de phase III évaluent l'efficacité, du point de vue de la survie sans progression et de la survie globale, du cabozantinib et du nivolumab par comparaison avec l'évérolimus
Therapy for advanced renal-cell cancer has evolved considerably in the past decade, with new agents greeted like “buried treasure,” although these agents come with substantial costs to both patients and the health system. Before 2005, the widely used systemic agents were cytokines — interferon alfa and interleukin-2, which yielded modest efficacy and substantial toxicity. Nevertheless, underlining the immunogenic nature of renal-cell cancer, durable complete responses occur in some patients who receive interleukin-2; these patients are mostly cured...
New England Journal of Medicine , éditorial en libre accès, 2014